 BURLINGAME, Calif.--BUSINESS WIRE--Humanigen, Inc. Nasdaq: HGEN Humanigen, a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumabTM, today announced that the Companys management team will participate in a fireside chat at the Jefferies Healthcare Conference being held from June 1-4, 2021. Management will discuss its lead product, lenzilumab, which recently completed a Phase 3 